HeartSciences Inc. has secured its first commercial SaaS revenue agreement with St. Vincent Health to deploy its MyoVista Insights platform, marking a key milestone from early adopter installations to revenue-generating deployments. MyoVista Insights is a cloud-based ECG management system that integrates AI to improve clinical workflows and is device-agnostic, designed to scale across healthcare facilities. The company expects more commercial agreements in the coming quarters as it gains market interest following its full launch at the American College of Cardiology Annual Scientific Session. This deal highlights HeartSciences' transition to mainstream commercial operations and its potential growth in healthcare technology adoption.
The global coffee substitute market, valued at $15.5 billion in 2025, is projected to grow at a 4.8% CAGR to reach $24.3 billion by 2035. Growth is fueled by rising consumer awareness of caffeine-related health issues and a shift towards clean-label,...
The global connected vehicle technology market, valued at $45.3 billion in 2025, is projected to grow at a CAGR of 11.4% to reach $129.2 billion by 2035. Growth is driven by the adoption of advanced driver assistance systems (ADAS), 5G connectivity e...
The global fish sauce market, valued at $3.1 billion in 2025, is projected to grow at a 5.3% CAGR to reach $5.1 billion by 2035. Growth is driven by the increasing global popularity of Southeast Asian cuisines and rising demand for natural, fermented...
Investor Gary Black predicts an initial boost for SpaceX investors following its IPO, driven by expedited inclusion in the Nasdaq-100 and S&P 500 indices and strong underwriter support from Goldman Sachs and Morgan Stanley. However, Black warns that ...
SpaceX is preparing for its IPO with plans to allocate up to 30% of shares to retail investors, a notably large retail offering. Platforms like Robinhood and Sofi allow retail investors to participate without minimum account balances, though they mus...
